Citations

Clear

133 citation(s) found for "Fernandes, B C".

Primary Lateral Sclerosis Natural History Study: Primary Lateral Sclerosis Functional Rating Scale and Other Outcomes Assessment
Lee, Ikjae , Jang, Grace E. , Sherman, Alexander , Johnston, Wendy , Fernandes, Joseph Americo, Habib, Ali A. , Maragakis, Nicholas J. , Shah, Jaimin , Zinman, Lorne , Floeter, Mary Kay, Ajroud‐Driss, Senda , Gwathmey, Kelly , Heiman‐Patterson, Terry , Jawdat, Omar, Kasarskis, Edward J. , Kisanuki, Yaz Y. , Wymer, James , Fournier, Christina , Hayat, Ghazala , Heitzman, Daragh, Lomen‐Hoerth, Catherine , Pulley, Michael , Scelsa, Stephen N. , Walk, David , Shoesmith, Christen , Sorenson, Eric J. , Elman, Lauren , Harms, Matthew , Hoover, Benjamin N., Yun, RN ByoungSook, Santella, Regina M. , Mitsumoto, Hiroshi , Group, for the PLS NHS Study, Diaz, Frank , Maragakis, Nicholas , Oskarsson, Björn , Goutman, Stephen A , Sorenson, Eric, Walk, David , Cheung, Ken , Diaz, Frank , Fernandes, J. Americo, Paganoni, Sabrina , Burke, Katherine M. , Oskarsson, Björn , Goutman, Stephen A. , Simmons, Zachary , Harms, Matthew B. , Hoover, Benjamin N., Group, for the PLS NHS Study

Mayo Clinic

Annals of Neurology | September 29, 2025 | Volume: 99 | Issue: 2 | Pages: 418-428

10.1002/ana.78056 | PMID 41020440 Get It

Objective The primary lateral sclerosis ( PLS ) consensus diagnostic criteria and functional rating scale ( PLSFRS ) were recently established to facilitate and optimize future PLS clinical trials. We examined the trajectory of the PLSFRS and other functional outcome measures and biomarkers in the PLS Natural History Study ( PLS NHS ) to understand their performance in this prospective cohort. Methods The PLS NHS is a prospective, longitudinal, multicenter study of people living with PLS in different diagnostic categories: early (disease duration <2 years); probable (2–4 years); and definite PLS (4–15 years). PLSFRS scores and other functional outcome measures were collected at baseline, 3‐, 6‐, 9‐, and 12‐month follow‐up visits. Baseline characteristics were compared between the groups. The slopes of the PLSFRS and other functional outcome measures over 12 months were examined in the overall cohort and subgroups using linear mixed‐effect models. The associations between baseline characteristics and the rate of PLSFRS decline were analyzed with linear regression models. Results A total of 76 participants were included: early (n = 6); probable (n = 26); and definite (n = 44) PLS . Baseline PLSFRS total scores were highest in the early PLS group, followed by the probable and definite PLS groups. In the overall cohort, the PLSFRS total score declined by 0.33 points/month (95% confidence interval [0.27–0.39], adjusted p < 0.05). The rate of decline was steepest in the early PLS group, followed by the probable and definite PLS groups. Baseline neurofilament light chain level was associated with the rate of PLSFRS decline over 1 year ( p = 0.001). Interpretation In PLS, the rate of functional decline, as measured by the PLSFRS total score, is faster during the early phase of the disease. Neurofilament light might serve as a prognostic biomarker in PLS. ANN NEUROL 2026;99:418–428
Sinonasal Tract Osteochondromyxoma: An Underrecognized Tumor Easily Mistaken for Nasal Chondromesenchymal Hamartoma
Bishop, Justin A., Alani, Ali, Fernandes, Igor Lima , Bacchi, Carlos E. , Klink, Daniel F., Marshall, Carrie B. , Folpe, Andrew L. , Bishop, Justin A. , Baumhoer, Daniel

Mayo Clinic

No container title available | September 25, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7594659/v1 Get It

Abstract Matrix-producing tumors of the sinonasal region are diagnostically challenging, with a large number of similar-appearing neoplasms having different prognoses, treatment strategies, and genetic syndrome associations. Osteochondromyxoma (OCM) is a very rare tumor known to be associated with Carney complex. Since its initial description in 2001, fewer than 20 cases have been reported, with the sinonasal tract being an apparently favored site. Herein we describe 6 new cases of sinonasal OCM.OCM cases with available slides were retrieved from the surgical pathology files of the authors’ practices. The tumors arose in 4 boys and 2 girls, ranging from 4 to 17 years (mean, 9.5 years). All presented with nasal obstruction and a mass. Radiologically the tumors presented as indolent-appearing, heterogeneous, calcified, expansile masses. Histologically the tumors all consisted of bland, normochromatic spindled to stellate cells in a myxoid to collagenized stroma, with variable amounts of cartilage and bone formation. Mitotic activity was very low and necrosis was absent. All demonstrated complete loss of PRKAR1A expression by immunohistochemistry. Of these 6 cases, 3 had been originally diagnosed as nasal chondromesenchymal hamartomas, and one as osteosarcoma. Treatment and follow up information were available for 5 patients: all were treated with surgery, with one also receiving chemotherapy after an initial osteosarcoma diagnosis. At the time of last clinical follow-up, all 5 patients were alive, one with residual disease. No patient was known to have other stigmata of Carney complex.Although rare, OCM preferentially occurs in the sinonasal tract, and therefore may be encountered by head and neck pathologists. Given their predilection for young patients and overlapping morphologic features, OCM are easily misdiagnosed as other matrix-forming sinonasal tumors, especially nasal chondromesenchymal hamartoma. Immunohistochemical demonstration of PRKAR1A loss is valuable for confirming an OCM diagnosis, which should prompt clinical investigation for the possibility of Carney complex.
Molecular, histologic, and clinical characterization of methylation class pleomorphic xanthoastrocytoma: An analysis of 469 tumors
Dampier, Christopher H. , Shah, Niharika, Neto, Osório Lopes Abath , Abdullaev, Zied , Alexandrescu, Sanda , Armstrong, Terri, Baker, Tiffany , Cathcart, Sahara , Chung, Hye‐Jung, Cimino, Patrick J. , Conway, Kyle , Dazelle, Karen , Etminam, Nima, Fernandes, Igor, Ferrone, Christina K. , Gilani, Ahmed , Gilbert, Mark, Gregory, Jason V. , Lee, Han Sung, Lopes, Maria Beatriz, Neill, Stewart G. , Ozer, Byram H. , Paulus, Werner, Penas‐Prado, Marta, Prinz, Marco , Pytel, Peter , Quezado, Martha , Raffeld, Mark , Rajan, Sharika, Reifenberger, Guido, Robinson, Lorraina , Schittenhelm, Jens , Thomas-Ogunniyi, Jaiyeola , Toland, Angus , Turakulov, Rust , Aldape, Kenneth , Cimino, Patrick J , Mao, Qinwen , Prinz, Marco , Ratliff, Miriam , Robinson, Lorraina , Schittenhelm, Jens , Thomas, Christian , Vaubel, Rachael A , Wu, Jing , Giannini, Caterina , Brandner, Sebastian , von Deimling, Andreas , Aldape, Kenneth , Dampier, Christopher H , Galbraith, Kristyn , Ebrahimi, Azadeh , Andreiuolo, Felipe , Cotter, Jennifer A. , Costa, Felipe D’Almeida , Ferman, Sima , Fernandes, Igor, Gregory, Jason, Ketchum, Courtney , Lee, Ina , Lopes, M. Beatriz S. , Mao, Qinwen , Marshall, Michael S. , McCord, Matthew , Nirschl, Jeffrey , Peñas-Prado, Marta , Schrimpf, Daniel , Singh, Omkar , Thomas, Christian , Thomas, Diana , Vaubel, Rachael A. , Wadhwani, Nitin R. , Giannini, Caterina , Snuderl, Matija , Deimling, Andreas von

Mayo Clinic

Neuro-Oncology Advances | July 21, 2025 | Volume: 7 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdaf089 | PMID 40735274 Get It

Abstract Background Methylation class pleomorphic xanthoastrocytoma (mcPXA) comprises tumors with the DNA methylation signature of classical PXA but with a wider histologic spectrum, including overlap with glioblastoma (GBM). Methods To clarify the histologic and molecular scope of mcPXA and characterize its clinical behavior, a cohort of 469 tumor samples from 458 patients matching to mcPXA by the DKFZ classifier (v12.6 score ≥0.85) was interrogated. Results Patient median age was 23 years (range 1-73 years) with a female predominance (259 female/199 male). CDKN2A/B homozygous deletion was observed in 406 of 469 (87%) samples. In samples tested for BRAF p.V600E mutations (n = 279), 240 (86%) harbored the mutation. A chr7+/chr10− pattern was observed in 103 of 469 (22%) samples. Among samples tested for TERT promoter mutations (n = 143), 32 (22%) harbored the mutation. Progression-free and overall survival of patients with mcPXA were comparable to patients with methylation class IDH-mutant astrocytoma, low grade, but a GBM-like subset (ie, cases with a pre-methylation working diagnosis of GBM) showed shorter survival. Histologic features of high grade, including palisading necrosis and microvascular proliferation, were prognostic in mcPXA. Compared to patients with BRAF p.V600E-altered GBM, patients with mcPXA were younger and had a lower frequency of TERT promoter mutations. Conclusion Tumors in mcPXA share molecular characteristics with histologically defined PXA, and high-grade histologic features can help predict their clinical behavior. The use of an epigenetic classification of PXA reveals that this group of tumors is more common than previously appreciated and warrants in-depth study to identify efficacious therapeutic options.
The Minnesota Conference proposed guidelines for education and training in clinical neuropsychology
Stringer, Anthony Y. , Fuchs, Kathleen , Edgar, Veronica Bordes , Correia, Stephen , Penna, Suzanne , Whiteside, Douglas M. , Bodin, Douglas, Butt, Sakina M. , Dodzik, Peter , Fernandes, Mary A. , Freece, Krista, Fuller, Richard, Getz, Glen E., Harder, Lana , Irani, Farzin , Janzen, Laura , Kaseda, Erin T. , Kramer, Megan , Kubu, Cynthia S. , Lafosse, Jose M., Lee-DaRocha, Jennifer, MacDonald, Beatriz , Strutt, Adriana M. , McBride, W.E., Mucci, Grace , Nayar, Kritika , Paltzer, June Yu, Ray, Courtney , Ready, Rebecca E. , Schmitt, Taylor Rose , Rush, Beth , Stanford, Lisa D., Patten, Ryan Van , Verroulx, Kris, Wilson, Jaime, Wright, Ingram , Zartman, Andrea L., Fujii, Daryl , Heffelfinger, Amy , Rey‐Casserly, Celiane , Whiteside, Douglas , Block, Cady, Calamia, Matthew , M Dotson, Vonetta , Johnstone, Brick , Kaseda, Erin , Madore, Michelle , Medina, Luis Daniel , Sperling, Scott , Stiers, William , Stricker, Nikki H , Bilder, Robert , Heffelfinger, Amy , Schmitter-Edgecombe, Maureen , Bristow, Thomas, Reyes, Anny , Block, Cady K. , Calamia, Matthew , Didehbani, Nyaz , Fuller, Richard, Harder, Lana, McBride, Will, Medina, Luis D. , Singh, Shifali M. , Sperling, Scott A. , Stricker, Nikki H. , Thornton, Allen E. , Vandermorris, Susan , Parsons, Thomas D. , Puente, Antonio E. , Roper, Brad L.

Mayo Clinic

The Clinical Neuropsychologist | July 2, 2025 | Volume: 40 | Issue: 2 | Pages: 331-375

10.1080/13854046.2025.2520957 | PMID 40604361 Get It

A curriculum for epilepsy surgery: A report from the Surgical Commission's Epilepsy Surgery Educational Task Force and the Educational Council of the ILAE
Dorfer, Christian , Enslin, Nico , Olivera, Tatiana von Hertwig Fernandes de, Wiebe, Samuel , Alotaibi, Faisal , Ali, Rushna , Englot, Dario J. , Cross, J. Helen , Ali, Rushna P, Dorfer, Christian , Englot, Dario J , Cross, Helen J , Nico Enslin, Johannes M , Muh, Carrie R. , Wang, Xiongfei , Wiebe, Samuel , McKhann, Guy M. , Damisah, Eyiyemisi C. , Singh, Gagandeep , Blümcke, Ingmar , Rydenhag, Bertil , Alonso‐Vanegas, Mario , Cukiert, Arthur

Mayo Clinic

Epileptic Disorders | June 26, 2025 | Volume: 27 | Issue: 5 | Pages: 718-728

10.1002/epd2.70054 | PMID 40569634 Get It

Abstract Objective There is a need to develop a comprehensive, formalized, and globally applicable epilepsy surgery curriculum in order to help standardize the quality of epilepsy surgery practice in the world. Methods The Epilepsy Surgery Educational Task Force of the ILAE developed a competency‐based epilepsy surgery educational curriculum comprised of four domains: Diagnosis, Counseling, Pre‐surgical Work‐up, and Surgical Techniques. To evaluate this educational curriculum, a survey questionnaire consisting of 11 items was sent out for feedback to ILAE and IESS members. The survey questionnaire asked respondents to rate the degree of importance of each competency on a five‐point scale that ranged from “extremely important” to “not at all important” and provided space for free text comments. All competencies that were rated as “slightly important” or “somewhat important” by more than 10% of responders, as well as all free text feedback comments, were fully reviewed, and the final curriculum was adjusted accordingly. Results One hundred and twenty‐two responses ( n = 122) were submitted by the ILAE and IESS communities. Seventy‐one percent (71.9%) of the responses came from neurosurgeons of varied experience and training levels. Ninety‐four percent (94.4%) of responders stated that they “support a curriculum to determine the competency of neurosurgeons participating in the care of people with epilepsy in my country,” and 94.3% confirmed that they “would be interested in taking or would recommend an ILAE course based on these competencies, that would provide an ILAE certificate of completion.” Relevant changes within the curriculum were made based on feedback. Significance The newly developed ILAE comprehensive epilepsy surgery educational curriculum has a high level of support from neurosurgeons and neurologists around the world and shows potential for broad acceptance and implementation.
Placebo‐Controlled, Randomized Double‐Blind N‐Of‐1 Trial to Study Safety and Potential Efficacy of TJ‐68 for Improving Muscle Cramps in Patients With Amyotrophic Lateral Sclerosis: A Pilot Study
Mitsumoto, Hiroshi , Oskarsson, Björn , Jang, Grace E. , Andrews, Howard , Johnson, Stephen A. , Shah, Jaimin , Fernandes, Joseph Americo, Andrews, Jinsy , Rao, Maya K., McElhiney, Martin , Oskarsson, Björn , Johnson, Stephen A , Shah, Jaimin S, Cheung, Ken , Fernandes, J. Americo

Mayo Clinic

Muscle & Nerve | June 23, 2025 | Volume: 72 | Issue: 3 | Pages: 485-492

10.1002/mus.28459 | PMID 40545904 Get It

ABSTRACTIntroduction/AimsMuscle cramps are a common symptom in amyotrophic lateral sclerosis (ALS). Ameliorating muscle cramps may improve quality of life in devastating diseases like ALS. A traditional Japanese medicine (Kampo, TJ‐68) is widely prescribed in Japan for muscle cramps. However, it is not available in the USA. This study evaluated the safety, tolerability, and efficacy of TJ‐68 in ALS.MethodsThis study was a double‐blind, randomized, placebo‐controlled crossover trial, consisting of four periods, conducted at three centers in the USA. Safety was evaluated using multiple measures. The primary efficacy outcome was the Visual Analog Scale for Muscle Cramps Affecting Overall Daily Activity (item #5 of the Muscle Cramp Scale (MCS)). The secondary outcomes included the remaining items of the MCS and the Clinical Global Impression of Changes (CGIC), among others. The study was planned to enroll 22 participants with ALS within 2 years.ResultsThe enrollment was slow and was completed with 11 participants. There were no serious safety issues and TJ‐68 was well tolerated. Although the primary outcome measure did not reach statistical significance (p = 0.35), several secondary measures showed significant results: MCS #1 triggering of cramps (p = 0.01), MCS #2 cramp frequency (p = 0.03), MCS Additional 1 change of motor behaviors (p = 0.02), and CGIC assessed by the evaluator (p = 0.009). Other outcome measures did not reach statistical significance.DiscussionThe study revealed that N‐of‐1 trial design can detect changes in a small sample size, and TJ‐68 appeared to be safe. Larger studies are needed to confirm the efficacy of TJ‐68.
Hyperinsulinemia-induced upregulation of adipocyte TPH2 contributes to peripheral serotonin production, metabolic dysfunction, and obesity
Park, Brian I., Reeves, Andrew R., Wilson, Robin A. , Fernandes, Sophia C., Buhman, Kimberly K. , Lytle, Kelli A. , Jensen, Michael D. , Greenberg, Andrew S. , Park, Brian I., Reeves, Andrew R., Zhu, Ying , Fernandes, Sophia C., Jensen, Michael

Mayo Clinic

Journal of Clinical Investigation | June 4, 2025 | Volume: 135 | Issue: 14 | Pages: No page available

10.1172/jci190765 | PMID 40455408 Get It

Tryptophan hydroxylase (TPH) is a rate-limiting enzyme for serotonin or 5-hydroxytryptamine (5-HT) synthesis. Previously, adipocyte TPH1 has been linked to increased adipose 5-HT, reduced brown adipose tissue (BAT) thermogenesis, and obesity. However, the role of TPH2, a neural isoform highly expressed in obese adipose tissue, is unknown. Here, we report that adipose tissue expression of TPH2 is dramatically elevated in mice with diet-induced obesity (DIO) and ob/ob mice, as well as in obese humans. In mice fed a high-fat diet, adipocyte TPH2 deficiency improved DIO-induced metabolic complications, enhanced BAT thermogenesis, and increased intestinal energy-harvesting efficiency without affecting adiposity. Conversely, TPH2 overexpression in epididymal adipocytes of chow-fed mice raised adipose and plasma 5-HT levels, suppressed BAT thermogenesis, and exacerbated obesity and metabolic dysfunction. We found that obesity-induced hyperinsulinemia upregulated adipocyte TPH2 expression via activation of mechanistic target of rapamycin complex 1 and SREBP1. In humans, TPH2 mRNA levels in subcutaneous adipose tissue, but not those of TPH1 , are positively correlated with fasting plasma insulin concentrations. In summary, our study demonstrates that obesity-associated increases in adipocyte TPH2 can regulate distal tissue physiology and energy metabolism, suggesting that TPH2 could be a potential therapeutic target for obesity and its associated complications.
Permissive central tolerance plus defective peripheral checkpoints license pathogenic memory B cells in CASPR2-antibody encephalitis
Sun, Bo , Fernandes, Dominique , Soltys, John , Paneva, Sofija , Harrison, Ruby , Harrison, Anna, Makuch, Mateusz , Fichtner, Miriam L. , Donat, Robert F. , Akdeniz, Deniz, Bayuangga, Halwan Fuad , Im, Min Gyu , Williams, Robyn , VASCONCELOS, ANA RAQUEL GOUVEIA , Thomsen, Selina, Fower, Andrew , Sun, Ruyue, Fox, Hannah , Mgbachi, Victor , Davies, Alexander J. , Tseng, Mandy , Handel, Adam E. , Kelly, Mark , Zhao, Meng , Bancroft, James , Bashford-Rogers, Rachael , Pluvinage, John V. , Dandekar, Ravi , Alvarenga, Bonny D. , Dustin, Lynn B. , Rinaldi, Simon , Owens, Raymond J. , Anthony, Daniel C. , Bennett, David , Davis, Simon J. , Wilson, Michael R. , O’Connor, Kevin C. , Carvalho, Ana Luı́sa , Irani, Sarosh R. , Kienzler, Anne-Kathrin , Paneva, Sofija , Harrison, Ruby , Harrison, Anna L , Fichtner, Miriam L , Bayuangga, Halwan , Im, Min Gyu , Vasconcelos, Ana , Fower, Andrew , Fox, Hannah , Davies, Alexander , Tseng, Mandy , Handel, Adam , Kelly, Mark , Zhao, Meng , Bancroft, James , Pluvinage, John V , Dandekar, Ravi , Alvarenga, Bonny D , Dustin, Lynn B , Rinaldi, Simon , Owens, Ray , Anthony, Daniel , Bennett, David L , Davis, Simon J , Wilson, Michael R , O'Connor, Kevin C , Carvalho, Ana Luisa , Irani, Sarosh R , Sun, Bo , Williams, Robyn L , Ramanathan, Sudarshini , Sun, Ruyue, Waters, Patrick

Mayo Clinic

Science Advances | April 16, 2025 | Volume: 11 | Issue: 16 | Pages: No page available

10.1126/sciadv.adr9986 | PMID 40238887 Get It

Autoantibody-mediated diseases targeting one autoantigen provide a unique opportunity to comprehensively understand the development of disease-causing B cells and autoantibodies. Convention suggests that such autoreactivities are generated during germinal center reactions. Here, we explore earlier immune checkpoints, focusing on patients with contactin-associated protein-like 2 (CASPR2)–autoantibody encephalitis. In both disease and health, high (~0.5%) frequencies of unmutated CASPR2-reactive naïve B cells were identified. By contrast, CASPR2-reactive memory B cells were exclusive to patients, and their B cell receptors demonstrated affinity-enhancing somatic mutations with pathogenic effects in neuronal cultures and mice. The unmutated, precursor memory B cell receptors showed a distinctive balance between strong CASPR2 reactivity and very limited binding across the remaining human proteome. Our results identify permissive central tolerance, defective peripheral tolerance, and autoantigen-specific tolerance thresholds in humans as sequential steps that license CASPR2-directed pathology. By leveraging the basic immunobiology, we rationally direct tolerance-restoring approaches, with an experimental paradigm applicable across autoimmunity.
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia
Rankin, Alexander W. , Hoang, Chloe, Semchenkova, Alexandra , Myers, Regina M. , Wang, Hao‐Wei , Kovach, Alexandra E. , Yuan, Constance M. , Colon, Dana Delgado, Vasseur, Loïc , John, Samuel , Lyons, Kaylyn Utley , Friedes, Barbara D., Alonso‐Saladrigues, Anna , Abdel‐Azim, Hisham , Balducci, Estelle , Aljudi, Ahmed Assim , Balsat, Marie , Biery, D. N. , Chamdin, Aghiad, Cuevo, Raymund S., Dickens, David S. , Duffner, Ulrich, Elliott, Michelle A. , Escherich, Gabriele , Fernandes, Sneha, Fitzjohn, Mandi R., Gahvari, Zhubin, He, Rui , Harrison, Cynthia , Hergott, Christopher A. , Hsieh, Emily M. , Larson, Daniel P. , Lee, Benjamin J. , Leguay, Thibaut , Mangaonkar, Abhishek A. , Mezger, Kerstin, Pacenta, Holly , Provost, Marlie R. M., Puri, Latika, Raikar, Sunil S. , Martinez, Armando, Bristol, Isabella Quijada, Murphy, Kyle, Reiman, Lauren T. , Redell, Michele S. , Reed, Kelly, Guépin, Gabrielle Roth, Savaşan, Süreyya , Schafernak, Kristian T. , Stevens, Alexandra M. , Talleur, Aimee C. , Carapia, Naomi Torres, Vargaftig, Jacques , Vatsayan, Anant , Wölfl, Matthias , Rives, Susana , Sasaki, Koji , Davis, Kara L. , Ghorashian, Sara , Jacoby, Elad , Попов, А. М. , Lamble, Adam J. , Rankin, Alexander W , Semchenkova, Alexandra , Myers, Regina M , Zerkalenkova, Elena , Wang, Hao-Wei , Kovach, Alexandra E , Yuan, Constance M , Vasseur, Loïc , Alonso-Saladrigues, Anna , Balducci, Estelle , Aljudi, Ahmed Assim , Chang, Bill H , Cuevo, Raymund S , De Moerloose, Barbara , Dickens, David S , Duployez, Nicolas , Elliott, Michelle Ann, Harrison, Cynthia , Kim, Annette S , Kuo, Dennis J , Larson, Daniel P , Lee, Benjamin J , Leguay, Thibaut , Lindsley, R Coleman , Puri, Latika , Raikar, Sunil S , Rubinstein, Jeremy , Schafernak, Kristian , Talleur, Aimee , Vatsayan, Anant , Wölfl, Matthias , Rives, Susana , Fabrizio, Vanessa A , Sasaki, Koji , Boissel, Nicolas , Rheingold, Susan R , Davis, Kara L , Ghorashian, Sara , Popov, Alexander , Shah, Nirali N , Silbert, Sara K. , Zerkalenkova, Elena , Colon, Dana Delgado, Bataller, Alex , Biery, D. Nathan, Chaer, Firas El , Grupp, Stephan A. , Pan, Jing , Martinez, Armando, Murphy, Kyle, Zhao, Liping, Aldoss, Ibrahim

Mayo Clinic

Blood | April 7, 2025 | Volume: 146 | Issue: 4 | Pages: 437-455

10.1182/blood.2024026655 | PMID 40193715 Get It

Abstract Lineage switch (LS), defined as the immunophenotypic transformation of acute leukemia, has emerged as a mechanism of relapse after antigen-targeted immunotherapy, which is associated with dismal outcomes. Through an international collaborative effort, we identified cases of LS after a host of antigen-targeted therapies (eg, CD19, CD22, CD38, and CD7), described how LS was diagnosed, reviewed treatment approaches, and analyzed overall outcomes for this form of postimmunotherapy relapse. Collectively, 75 cases of LS were evaluated, including 53 (70.7%) cases of B-cell acute lymphoblastic leukemia (B-ALL) transforming to acute myeloid leukemia (AML), 17 (22.7%) cases of B-ALL transforming to mixed phenotypic acute leukemia (MPAL)/acute leukemias of ambiguous lineage (ALAL), and 5 (6.7%) cases of rare LS presentation (ie, T-cell ALL to AML). An additional 10 cases with incomplete changes in immunophenotype, referred to as “lineage drift” were also described. With a primary focus on the 70 cases of LS from B-ALL to AML or MPAL/ALAL, LS emerged at a median of 1.5 months (range, 0-36.5) after immunotherapy, with 81.4% presenting with LS within the first 6 months from the most proximal immunotherapy. Although most involved KMT2A rearrangements (n = 45, 64.3%), other rare cytogenetic and/or molecular alterations were uniquely observed. Treatment outcomes were generally poor, with remission rates of &lt;40%. The median overall survival after LS diagnosis was 4.8 months. Outcomes were similarly poor for those with rare immunophenotypes of LS or lineage drift. This global initiative robustly categorizes lineage changes after immunotherapy and, through enhanced understanding, establishes a foundation for improving outcomes of LS.
Systemic antitumor immune response of doped yttria nanoscintillators under low-dose x-ray irradiation
Sahin, Onur , Mackeyev, Yuri , Vijay, Geraldine V. , Roy, Soumyabrata , Ashokkumar, Meiyazhagan , Zahra, Yasmin , Tezcan, Okan , Gonzalez, Valeria , Abousaida, Belal , Wagner, Holden R. , FERNANDES, P. S. , Mowzoon-Mogharrabi, Riaz , Venkatesulu, Bhanu Prasad , Hsieh, Cheng‐En , Kim, Joseph Byung-Kyu, Raghuram, Subhiksha, Zhang, Xiang , Miller, Kristen A. , Gao, Guanhui , Cho, Sang Hyun , Papineni, Rao V. , Ajayan, Pulickel M., Krishnan, Sunil , Meiyazhagan, Ashokkumar , Fernandes, Pearl , Kim, Joseph B K, Papineni, Rao V L , Krishnan, Sunil , Hsieh, Rodney Cheng-En , Gonzalez, Valeria V , Mackeyev, Yuri , Mowzoon-Mogharrabi, Riaz , Singh, Pankaj Kumar , Ajayan, Pulickel M.

Mayo Clinic

Science Advances | March 26, 2025 | Volume: 11 | Issue: 13 | Pages: No page available

10.1126/sciadv.adr4008 | PMID 40138411 Get It

Inadequate light penetration in tissues restricts photodynamic therapy to treating only superficial tumors. To enable x-ray–excited photodynamic therapy (XPDT) that targets deep-seated tumors, we synthesized a nanoscintillator-photosensitizer complex containing 5% Eu-doped Y 2 O 3 fluorescing at 611 nanometers and decorated with SiO 2 containing the scintillation-coupled photosensitizer methylene blue and a polyethylene glycol coating [PEGylated Y 2 O 3 :Eu@SiO 2 -methylene blue (pYSM)]. When irradiated, pYSMs generate singlet oxygen species in vitro, causing cytotoxicity with hallmarks of immunogenic cell death (calreticulin translocation to the cell membrane). Intravenously administered pYSMs home passively to pancreatic tumor xenografts and, upon 10 gray irradiation, cause significant tumor regression ( P < 0.01). On combining XPDT with anti-PD1 immunotherapy, a distant nonirradiated tumor also regresses via an increase in intratumoral activated CD8 + cytotoxic T cells. Collectively, we advance a systemically delivered XPDT strategy that mediates an antitumor effect in both irradiated and nonirradiated (abscopal) tumors when coupled with immunotherapy, converting an immunologically “cold” tumor to an immunologically “hot” tumor.